Insights

Addressing Unmet Needs in Multiple Myeloma
October 09, 2018 – 
Amrita Krishnan, MD, FACP, considers the greatest unmet needs in the treatment of multiple myeloma and discusses the efforts being undertaken to address them.
Second Myeloma Relapse and Beyond: Upcoming Strategies
October 02, 2018 – 
Amrita Krishnan, MD, FACP, reflects on the potential role of novel therapies and strategies, such as immuno-oncology or targeted agents, at the second relapse of multiple myeloma and beyond.
Selecting Treatment at First Relapse of Multiple Myeloma
October 02, 2018 – 
Amrita Krishnan, MD, FACP, discusses what agents or regimens one should consider at first relapse of multiple myeloma, particularly given clinical data on incremental changes in therapy.
Optimizing Maintenance Therapy in Multiple Myeloma
September 25, 2018 – 
Amrita Krishnan, MD, FACP, offers her perspective on optimal approaches to maintenance therapy in multiple myeloma regarding agent selection, potential risk, and duration.
Frontline Therapy's Impact on Later Treatment in MM
September 25, 2018 – 
Amrita Krishnan, MD, FACP, considers the impact that frontline treatment may have on later lines of therapy and whether or not this factors into which frontline regimen is used for multiple myeloma.
Multiple Myeloma: Frontline Daratumumab Combinations
September 18, 2018 – 
Amrita Krishnan, MD, FACP, elucidates various combination treatment approaches making use of daratumumab in the frontline setting for patients with newly diagnosed multiple myeloma.
Frontline Therapy Options for Multiple Myeloma
September 18, 2018 – 
Amrita Krishnan, MD, FACP, provides an overview of frontline treatment options for patients with newly diagnosed multiple myeloma, given a shift in the paradigm toward 4-drug combination strategies.
Approaching Upfront Treatment for Multiple Myeloma
September 12, 2018 – 
Amrita Krishnan, MD, FACP, shares insight on the goals and factors that affect frontline therapy selection for patients with newly diagnosed multiple myeloma and explains the potential value of minimal residual disease.
Advent of Combination Strategies in Multiple Myeloma
September 12, 2018 – 
Amrita Krishnan, MD, FACP, reflects on the value of combination therapy approaches in multiple myeloma and considers whether they have modified transplant’s role in sequencing.
Using Antiangiogenic Therapy in NSCLC in the Future
September 11, 2018 – 
H. Jack West, MD, predicts how the therapeutic landscape in non–small cell lung cancer is likely to evolve based on emerging data and remarks on the potential of antiangiogenic therapy in combination with other treatment strategies in appropriate patients.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!